Viatris (VTRS)
Technical, fundamental, and sentiment analysis with recent related videos.
VTRS rates Neutral overall. The fundamental read is neutral: the company passes 5 of 9 quality tests on the Piotroski F-Score; balance sheet is flagged Distress (Altman Z = 0.77); revenue is declining about 4.2% per year; net income is declining about 97.4% per year. The technical picture is bullish: price is 19.6% above the 200-day moving average; 8.4% above the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bullish (composite 76/100), based on 6 news articles from recent coverage.
Revenue 3-year avg -4.2%. Net income 3-year avg -97.4%.
Price vs 20DMA +4.5%. RSI 62.37. Bollinger state: Inside Bands.
Composite score 76/100 from the AI judge, based on 6 news items, 0 television segments, and 0 videos.
Latest Market Read
Viatris shows a split picture: fundamentals lean negative, revenue averaged -4.2% per year and net income averaged -97.4% per year over three years, but that weakness has not pushed the Fundamental badge out of Neutral. Technicals are Bullish: price sits above its 20-day moving average, the Relative Strength Index (RSI), a momentum reading, is 62.4, and the stock trades inside its Bollinger Bands. Sentiment is Bullish with a 76 composite. Those strong technical and sentiment signals counter the weak fundamentals, producing an Overall Neutral rating.
Recent news: The coverage is predominantly positive: multiple items highlight FDA approval of RYZUMVI for presbyopia and Viatris's agreement to acquire Pacira BioSciences, with the approval and deal arriving ahead of quarterly earnings and seen as potential near-term catalysts. Some neutral pieces note dividend upside depends on management execution and compare Viatris's quarter versus peers, but the approval, M&A activity, and strong recent total return drive an overall constructive tone.
Latest Videos
- No qualified videos yet.